Compare TG Therapeutics Inc (TGTX) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? TG Therapeutics Inc trades at $55.11 (market cap $8.16B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.48 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 9× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| TGTX | VTIP | |
|---|---|---|
Market Cap | $8.16B | $73.20B |
Volume | 1,735,121 | 2,511,360 |
Sector | Health | — |
52-Week High | $59.06 | $50.46 |
52-Week Low | $26.94 | $48.38 |
Typical Hold Time | 16 Days | 91 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
VTIP trades at $48.46, showing minimal daily movement with a slight decline of 0.01%. Technical indicators present a mixed picture with bearish moving averages but bullish oscillators, including oversold RSI readings. The ETF focuses on short-term inflation-protected securities, offering protection against rising inflation while minimizing interest rate sensitivity. Recent institutional activity shows increased positions from firms like NewEdge Advisors and 55 North Private Wealth.
The outlook for VTIP remains tied to inflation dynamics and Federal Reserve policy. With inflation persisting above the 2% target, short-duration TIPS provide strategic hedging value. However, the fund faces risks from potential Fed policy shifts and real yield fluctuations. Current technical weakness suggests near-term pressure, but oversold conditions may present entry opportunities for inflation-conscious investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
